Physician profile
Ashte K Collins
NPI 1295902625
$1,034,498.35
in general payments reported to CMS, 2019-2025
23 companies · $244K in 2025
The $244K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148K · 2020: $62K · 2021: $81K · 2022: $156K · 2023: $144K · 2024: $199K · 2025: $244K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $347K · Travel and Lodging: $96K · Consulting Fee: $63K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $57K · Food and Beverage: $21K · Honoraria: $3,375 · Charitable Contribution: $450 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $346,773.00 |
| Travel and Lodging | $96,085.35 |
| Consulting Fee | $62,675.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $56,850.00 |
| Food and Beverage | $21,470.92 |
| Honoraria | $3,375.00 |
| Charitable Contribution | $450.00 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $312,355.23 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals Lp | $226,738.10 | 2019-2025 | Lokelma, Farxiga |
| Travere Therapeutics, INC. | $179,770.98 | 2022-2025 | Filspari |
| Akebia Therapeutics INC | $169,204.29 | 2019-2025 | Vafseo, Auryxia |
| Mallinckrodt Enterprises LLC | $90,436.56 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $40,190.52 | 2019-2025 | Jynarque |
| Ani Pharmaceuticals, INC. | $4,594.35 | 2023 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $4,438.46 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,700.00 | 2022 | |
| Novo Nordisk INC | $2,291.03 | 2021-2025 | Wegovy |
| Vifor Pharma, INC. | $401.88 | 2021-2025 | Veltassa, Korsuva |
| Amgen INC. | $379.64 | 2019-2025 | Tavneos |
| Ardelyx, INC. | $265.54 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $222.72 | 2023-2025 | Benlysta, Jesduvroq |
| Aurinia Pharma U.S., INC. | $162.41 | 2022-2024 | Lupkynis |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $93.73 | 2023 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $65.08 | 2019-2024 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $52.64 | 2023-2024 | |
| Lilly USA, LLC | $43.83 | 2024 | Jardiance |
| Baxter Healthcare | $27.82 | 2023 | Renal - Pd |
| Genentech USA, INC. | $23.67 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.62 | 2025 | |
| Alnylam Pharmaceuticals INC. | $18.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashte Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.